tert-butyl (2-((5-formyl-2-(methylthio)pyrimidin-4-yl)amino)ethyl) carbamate | 1189532-29-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: tert-butyl (2-((5-formyl-2-(methylthio)pyrimidin-4-yl)amino)ethyl) carbamate
• 英文别名: tert-butyl N-[2-[(5-formyl-2-methylsulfanylpyrimidin-4-yl)amino]ethyl]carbamate
• CAS: 1189532-29-3
• 化学式: C₁₃H₂₀N₄O₃S
• 分子量: 312.393
• InChiKey: KAAIXKGTSQSSKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl (2-((5-formyl-2-(methylthio)pyrimidin-4-yl)amino)ethyl) carbamate 在 盐酸 、 potassium carbonate 、 N,N-二异丙基乙胺 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 8-(2-aminoethyl)-6-[2-chloro-4-(6-methylpyrazin-2-yl)phenyl]-2-[[(3R)-oxolan-3-yl]amino]pyrido[2,3-d]pyrimidin-7-one
  参考文献：
  名称：

  PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS

  摘要：

  本文提供了PAK抑制剂以及利用PAK抑制剂治疗细胞增殖性疾病和/或中枢神经系统疾病的方法。

  公开号：

  US20130116263A1
• 作为产物：
  描述：

  4-氯-2-甲硫基嘧啶-5-羧酸乙酯 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 反应 2.0h， 生成 tert-butyl (2-((5-formyl-2-(methylthio)pyrimidin-4-yl)amino)ethyl) carbamate
  参考文献：
  名称：

  PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS

  摘要：

  本文提供了PAK抑制剂以及利用PAK抑制剂治疗细胞增殖性疾病和/或中枢神经系统疾病的方法。

  公开号：

  US20130116263A1

文献信息

• Chemokine Receptor Modulators
  申请人：Clark Michael P.

  公开号：US20100029634A1

  公开（公告）日：2010-02-04

  The invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and/or esters thereof. These compounds, and pharmaceutical composition comprising such compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers

  该发明提供了公式(I)化合物及其药学上可接受的盐、溶剂合物、互变异构体、立体异构体和/或酯。这些化合物和包含这些化合物的药物组合物对于治疗或预防HIV感染以及治疗增生性疾病，如抑制各种癌症的转移具有用处。
• [EN] COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES<br/>[FR] COMPOSÉS DE LIAISON À CDK2 COVALENTS UTILISÉS À DES FINS THÉRAPEUTIQUES
  申请人：UMBRA THERAPEUTICS INC

  公开号：WO2022187693A1

  公开（公告）日：2022-09-09

  Heteroaryl sulfonyl compounds and compositions that have a CDK2 Recognition Moiety bound to an electrophile for the selective covalent modification of CDK2 to treat CDK2-mediated disorders are described.

  本文描述了具有CDK2识别基团结合到亲电体的杂环磺酰化合物和组合物，用于选择性共价修饰CDK2以治疗CDK2介导的疾病。
• 2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant
  作者：Xianglong Hu、Qiuju Xun、Tao Zhang、Su-Jie Zhu、Qian Li、Linjiang Tong、Mengzhen Lai、Tao Huang、Cai-Hong Yun、Hua Xie、Ke Ding、Xiaoyun Lu

  DOI：10.1016/j.cclet.2019.09.044

  日期：2020.5

  Extensive structure-activity relationships (SARs) study of JND3229 was conducted to yield a series of new reversible 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidine privileged scaffold as EGFR(C797S )inhibitors. One of the most potent compound 6i potently suppressed EGFR(L858R/T790M/C797S) kinase with an IC50 value of 3.1 nmol/L, and inhibited the proliferation of BaF3 cells harboring EGFR-(L858R/T790M/C797S) and EGER(19D/T790M/C797S) mutants with IC50 values of 290 nmol/L and 316 nmol/L, respectively. Further, 6i dose-dependently induced suppression of the phosphorylation of EGFR-(L858R/T790M/C797S) and EGER(19D/T790M/C797S) in BaF3 cells. Compound 6i may serve as a promising lead compound for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients. (C) 2019 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.
• Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties
  作者：Shilin Xu、Tianfeng Xu、Lianwen Zhang、Zhang Zhang、Jinfeng Luo、Yingxue Liu、Xiaoyun Lu、Zhengchao Tu、Xiaomei Ren、Ke Ding

  DOI：10.1021/jm4012388

  日期：2013.11.14

  Structural optimization of a series of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl compounds, potential new irreversible EGFR inhibitors, was performed to improve pharmacokinetic properties of the compounds. This led to compound 2v with improved aqueous solubility and good pharmacokinetic properties which at the nanomolar level potently inhibits gefitinib-resistant EGFR(L858R/T790M) kinase and displays strong antiproliferative activity against H1975 nonsmall cell lung cancer cells. The new inhibitor also shows promising antitumor efficacy in a murine EGFR(L858R/T790M)-driven H1975 xenograft model without effect on body weight. These studies provide new lead compounds for further development of drugs for treatment of gefitinib-resistant nonsmall cell lung cancer patients.
• CHEMOKINE RECEPTOR MODULATORS
  申请人：Altiris Therapeutics

  公开号：EP2262808B1

  公开（公告）日：2013-08-14